zum Inhalt

Ph.D. Hanspeter ROTTENSTEINER Head, Research Gene Therapy EU, Shire Austria GmbH, Orth an der Donau

CV

1998 Ph.D. in Biochemistry, University of Vienna
1999-2002 Postdoctoral Research, Freie Universität Berlin
2002 Assistant Professor, Ruhr-Universität Bochum
2003-2007 Professor in Physiological Chemistry, Bochum
2007-2014 Head of Recombinant Products, Global Research, Baxter, Vienna
2014-2016 Research Gene Therapy, Baxalta Innovations, Vienna
since 2016 Head, Research Gene Therapy EU, Shire Austria GmbH, Orth an der Donau

Mitgliedschaften

American Society for Gene and Cell Therapy

Publikationen

Weber A, Engelmaier A, Voelkel D, Pachlinger R, Scheiflinger F, Monahan PE, Rottensteiner H.: "Development of methods for the selective measurement of the single amino acid exchange variant coagulation factor IX Padua." Mol Ther Methods Clin Dev., 2018
Verhenne S, Vandeputte N, Pareyn I, Izsvák Z, Rottensteiner H, Deckmyn H, De Meyer SF, Vanhoorelbeke K.: "Long-term prevention of congenital thrombotic thrombocytopenic purpura in ADAMTS13 knockout mice by sleeping beauty transposon-mediated gene therapy." Arterioscler Thromb Vasc Biol., 2017
Plaimauer B, Schiviz A, Kaufmann S, Höllriegl W, Rottensteiner H, Scheiflinger F.: "Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13.", J Thromb Haemost., 2015
Grillberger R, Casina VC, Turecek PL, Zheng XL, Rottensteiner H, Scheiflinger F.: "Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.", Haematologica., 2014